REPLReplimune, Inc.Running, no new patients
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Cutaneous Squamous Cell Carcinoma · Advanced Cutaneous Squamous Cell Carcinoma · Metastatic Cutaneous Squamous Cell Carcinoma
14Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2025, none posted yet
Counts until it's fixed
- +3.9
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 10, fading over time
Worry score14
Score over time
- Stage
- Phase 2
- Patients
- 231 (final count)
- Started
- Oct 8, 2019
- Main results expected
- Sep 2025
- Fully finished
- Sep 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) according to blinded independent review
Measured over: up to 5 years
Complete Response Rate (CRR) according to blinded independent review
Measured over: up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-09-01, no fading
- insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04050436 · record last updated 2025-01-27 · checked 2026-11-09 15:36 UTC